| Year |
Citation |
Score |
| 2019 |
Andhavarapu S, Mubariz F, Arvas M, Bever C, Makar TK. Interplay between ER stress and autophagy: A possible mechanism in multiple sclerosis pathology. Experimental and Molecular Pathology. PMID 31047874 DOI: 10.1016/J.Yexmp.2019.04.016 |
0.335 |
|
| 2017 |
Gerzanich V, Makar TK, Guda PR, Kwon MS, Stokum JA, Woo SK, Ivanova S, Ivanov A, Mehta RI, Morris AB, Bryan J, Bever CT, Marc Simard J. Salutary effects of glibenclamide during the chronic phase of murine experimental autoimmune encephalomyelitis. Journal of Neuroinflammation. 14: 177. PMID 28865458 DOI: 10.1186/S12974-017-0953-Z |
0.32 |
|
| 2016 |
Nimmagadda VK, Makar TK, Chandrasekaran K, Sagi AR, Ray J, Russell JW, Bever CT. SIRT1 and NAD+ precursors: Therapeutic targets in multiple sclerosis a review. Journal of Neuroimmunology. PMID 27474445 DOI: 10.1016/J.Jneuroim.2016.07.007 |
0.366 |
|
| 2016 |
Makar TK, Nimmagadda VK, Singh IS, Lam K, Mubariz F, Judge SI, Trisler D, Bever CT. TrkB agonist, 7,8-dihydroxyflavone, reduces the clinical and pathological severity of a murine model of multiple sclerosis. Journal of Neuroimmunology. 292: 9-20. PMID 26943953 DOI: 10.1016/J.Jneuroim.2016.01.002 |
0.31 |
|
| 2015 |
Haselkorn JK, Hughes C, Rae-Grant A, Henson LJ, Bever CT, Lo AC, Brown TR, Kraft GH, Getchius T, Gronseth G, Armstrong MJ, Narayanaswami P. Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 85: 1896-903. PMID 26598432 DOI: 10.1212/Wnl.0000000000002146 |
0.334 |
|
| 2015 |
Makar TK, Gerzanich V, Nimmagadda VK, Jain R, Lam K, Mubariz F, Trisler D, Ivanova S, Woo SK, Kwon MS, Bryan J, Bever CT, Simard JM. Silencing of Abcc8 or inhibition of newly upregulated Sur1-Trpm4 reduce inflammation and disease progression in experimental autoimmune encephalomyelitis. Journal of Neuroinflammation. 12: 210. PMID 26581714 DOI: 10.1186/S12974-015-0432-3 |
0.309 |
|
| 2015 |
Kruszewski AM, Rao G, Tatomir A, Hewes D, Tegla CA, Cudrici CD, Nguyen V, Royal W, Bever CT, Rus V, Rus H. RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis. Experimental and Molecular Pathology. 99: 498-505. PMID 26407760 DOI: 10.1016/J.Jns.2015.08.125 |
0.321 |
|
| 2015 |
Culpepper WJ, Wallin MT, Magder LS, Perencevich E, Royal W, Bradham DD, Cutter G, Bever CT. VHA Multiple Sclerosis Surveillance Registry and its similarities to other contemporary multiple sclerosis cohorts. Journal of Rehabilitation Research and Development. 52: 263-72. PMID 26220064 DOI: 10.1682/Jrrd.2014.07.0172 |
0.347 |
|
| 2014 |
Minden SL, Feinstein A, Kalb RC, Miller D, Mohr DC, Patten SB, Bever C, Schiffer RB, Gronseth GS, Narayanaswami P. Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 82: 174-81. PMID 24376275 DOI: 10.1212/Wnl.0000000000000013 |
0.303 |
|
| 2013 |
Nimmagadda VK, Bever CT, Vattikunta NR, Talat S, Ahmad V, Nagalla NK, Trisler D, Judge SI, Royal W, Chandrasekaran K, Russell JW, Makar TK. Overexpression of SIRT1 protein in neurons protects against experimental autoimmune encephalomyelitis through activation of multiple SIRT1 targets. Journal of Immunology (Baltimore, Md. : 1950). 190: 4595-607. PMID 23547115 DOI: 10.4049/Jimmunol.1202584 |
0.305 |
|
| 2012 |
Yadav V, Bourdette DN, Bowen JD, Lynch SG, Mattson D, Preiningerova J, Bever CT, Simon J, Goldstein A, Burrows GG, Offner H, Ferro AJ, Vandenbark AA. Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study. Autoimmune Diseases. 2012: 954739. PMID 22548151 DOI: 10.1155/2012/954739 |
0.315 |
|
| 2012 |
Royal W, Lee-Wilk T, Wallin M, Bever C, Kane R, Maloni H, Finkelstein J, Cha E, McCarthy M, Levin M, Tyor W, Culpepper J, Mitchell L, Zhan M. CXCR3+ Naive T Helper Cell Percentages Correlate with Neuropsychological Test Abnormalities in Patients with MS (P04.102) Neurology. 78: P04.102-P04.102. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P04.102 |
0.324 |
|
| 2011 |
McDowell TY, Amr S, Culpepper WJ, Langenberg P, Royal W, Bever C, Bradham DD. Sun exposure, vitamin D intake and progression to disability among veterans with progressive multiple sclerosis. Neuroepidemiology. 37: 52-7. PMID 21822026 DOI: 10.1159/000329258 |
0.312 |
|
| 2011 |
McDowell TY, Amr S, Culpepper WJ, Langenberg P, Royal W, Bever C, Bradham DD. Sun exposure, vitamin D and age at disease onset in relapsing multiple sclerosis. Neuroepidemiology. 36: 39-45. PMID 21160231 DOI: 10.1159/000322512 |
0.301 |
|
| 2010 |
Cheng EM, Crandall CJ, Bever CT, Giesser B, Haselkorn JK, Hays RD, Shekelle P, Vickrey BG. Quality indicators for multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 16: 970-80. PMID 20562162 DOI: 10.1177/1352458510372394 |
0.327 |
|
| 2010 |
McDowell TY, Amr S, Langenberg P, Royal W, Bever C, Culpepper WJ, Bradham DD. Time of birth, residential solar radiation and age at onset of multiple sclerosis. Neuroepidemiology. 34: 238-44. PMID 20299805 DOI: 10.1159/000297749 |
0.325 |
|
| 2009 |
Makar TK, Bever CT, Singh IS, Royal W, Sahu SN, Sura TP, Sultana S, Sura KT, Patel N, Dhib-Jalbut S, Trisler D. Brain-derived neurotrophic factor gene delivery in an animal model of multiple sclerosis using bone marrow stem cells as a vehicle. Journal of Neuroimmunology. 210: 40-51. PMID 19361871 DOI: 10.1016/J.Jneuroim.2009.02.017 |
0.32 |
|
| 2008 |
Kane RL, Bever CT, Ehrmantraut M, Forte A, Culpepper WJ, Wallin MT. Teleneurology in patients with multiple sclerosis: EDSS ratings derived remotely and from hands-on examination. Journal of Telemedicine and Telecare. 14: 190-4. PMID 18534953 DOI: 10.1258/Jtt.2008.070904 |
0.337 |
|
| 2008 |
Makar TK, Trisler D, Bever CT, Goolsby JE, Sura KT, Balasubramanian S, Sultana S, Patel N, Ford D, Singh IS, Gupta A, Valenzuela RM, Dhib-Jalbut S. Stem cell based delivery of IFN-beta reduces relapses in experimental autoimmune encephalomyelitis. Journal of Neuroimmunology. 196: 67-81. PMID 18471898 DOI: 10.1016/J.Jneuroim.2008.02.014 |
0.31 |
|
| 2006 |
Judge SI, Lee JM, Bever CT, Hoffman PM. Voltage-gated potassium channels in multiple sclerosis: Overview and new implications for treatment of central nervous system inflammation and degeneration. Journal of Rehabilitation Research and Development. 43: 111-22. PMID 16847777 DOI: 10.1682/Jrrd.2004.09.0116 |
0.354 |
|
| 2006 |
Judge SI, Bever CT. Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacology & Therapeutics. 111: 224-59. PMID 16472864 DOI: 10.1016/J.Pharmthera.2005.10.006 |
0.347 |
|
| 2005 |
Macclellan LR, Bradham DD, Whitall J, Volpe B, Wilson PD, Ohlhoff J, Meister C, Hogan N, Krebs HI, Bever CT. Robotic upper-limb neurorehabilitation in chronic stroke patients. Journal of Rehabilitation Research and Development. 42: 717-22. PMID 16680609 DOI: 10.1682/Jrrd.2004.06.0068 |
0.302 |
|
| 2005 |
Graber J, Zhan M, Ford D, Kursch F, Francis G, Bever C, Panitch H, Calabresi PA, Dhib-Jalbut S. Interferon-beta-1a induces increases in vascular cell adhesion molecule: implications for its mode of action in multiple sclerosis. Journal of Neuroimmunology. 161: 169-76. PMID 15748956 DOI: 10.1016/J.Jneuroim.2004.11.017 |
0.322 |
|
| 2003 |
Giovannoni G, Bever CT. Patients with clinically isolated syndromes suggestive of MS: does MRI allow earlier diagnosis? Neurology. 60: 6-7. PMID 12525709 DOI: 10.1212/Wnl.60.1.6 |
0.35 |
|
| 2001 |
Li QQ, Bever CT. Th1 cytokines stimulate RANTES chemokine secretion by human astroglial cells depending on de novo transcription. Neurochemical Research. 26: 125-133. PMID 11478739 DOI: 10.1023/A:1011042711631 |
0.335 |
|
| 2001 |
Schwid SR, Bever CT. The cost of delaying treatment in multiple sclerosis: What is lost is not regained Neurology. 58: 1620-1620. PMID 11425925 DOI: 10.1212/Wnl.56.12.1620 |
0.315 |
|
| 2001 |
Li QQ, Bever CT. Comparison of RANTES chemokine induction by Th1 cytokines in human astroglial cell lines. International Journal of Molecular Medicine. 8: 95-101. PMID 11408956 DOI: 10.3892/Ijmm.8.1.95 |
0.32 |
|
| 2001 |
Li QQ, Burt DR, Bever CT. Glatiramer acetate inhibition of tumor necrosis factor‐α‐induced RANTES expression and release from U‐251 MG human astrocytic cells Journal of Neurochemistry. 77: 1208-1217. PMID 11389171 DOI: 10.1046/J.1471-4159.2001.00327.X |
0.326 |
|
| 2001 |
Li Q, Bever C, Burt D, Judge S, Trisler G. Induction of RANTES chemokine expression in human astrocytic cells is dependent upon activation of NF-κB transcription factor International Journal of Molecular Medicine. 7: 527-533. PMID 11295116 DOI: 10.3892/Ijmm.7.5.527 |
0.302 |
|
| 2001 |
Li QQ, Bever CT. Glatiramer acetate blocks interleukin-1-dependent nuclear factor-κB activation and RANTES expression in human U-251 MG astroglial cells Molecular Brain Research. 87: 48-60. PMID 11223159 DOI: 10.1016/S0169-328X(00)00282-5 |
0.314 |
|
| 1999 |
Bever CT, Rosenberg GA. Matrix metalloproteinases in multiple sclerosis: targets of therapy or markers of injury? Neurology. 53: 1380-1. PMID 10534237 DOI: 10.1212/Wnl.53.7.1380 |
0.334 |
|
| 1996 |
Bever CT, Anderson PA, Leslie J, Panitch HS, Dhib-Jalbut S, Khan OA, Milo R, Hebel JR, Conway KL, Katz E, Johnson KP. Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial. Neurology. 47: 1457-62. PMID 8960727 DOI: 10.1212/Wnl.47.6.1457 |
0.331 |
|
| 1995 |
Bever CT, Grattan L, Panitch HS, Johnson KP. The Brief Repeatable Battery of Neuropsychological Tests for Multiple Sclerosis: a preliminary serial study. Multiple Sclerosis (Houndmills, Basingstoke, England). 1: 165-9. PMID 9345448 DOI: 10.1177/135245859500100306 |
0.334 |
|
| 1995 |
Bever CT, Anderson PA, Smith GV, Panitch HS, Johnson KP. Isometric Measurement of Hamstrings and Quadriceps Strength in Multiple Sclerosis Patients: Sensitivity and Variability: Neurorehabilitation and Neural Repair. 9: 221-227. DOI: 10.1177/154596839500900405 |
0.303 |
|
| 1995 |
Bever CT. 4-Aminopyridine: Use in Multiple Sclerosis Cns Drug Reviews. 1: 261-279. DOI: 10.1111/J.1527-3458.1995.Tb00286.X |
0.317 |
|
| 1994 |
Bever CT, Young D, Anderson PA, Krumholz A, Conway K, Leslie J, Eddington N, Plaisance KI, Panitch HS, Dhib-Jalbut S. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology. 44: 1054-9. PMID 8208399 DOI: 10.1212/Wnl.44.6.1054 |
0.331 |
|
| 1994 |
Bever CT, Panitch HS, Johnson KP. Increased cathepsin B activity in peripheral blood mononuclear cells of multiple sclerosis patients. Neurology. 44: 745-8. PMID 8164836 DOI: 10.1212/Wnl.44.4.745 |
0.373 |
|
| 1994 |
Bever CT. The current status of studies of aminopyridines in patients with multiple sclerosis. Annals of Neurology. 36. PMID 8017870 DOI: 10.1002/Ana.410360728 |
0.353 |
|
| 1993 |
Panitch HS, Bever CT. Clinical trials of interferons in multiple sclerosis. What have we learned? Journal of Neuroimmunology. 46: 155-64. PMID 7689585 DOI: 10.1016/0165-5728(93)90245-T |
0.368 |
|
| 1991 |
Bever CT, Panitch HS, Levy HB, McFarlin DE, Johnson KP. Gamma-interferon induction in patients with chronic progressive MS. Neurology. 41: 1124-7. PMID 1829795 DOI: 10.1212/Wnl.41.7.1124 |
0.358 |
|
| 1990 |
Bever CT, Leslie J, Camenga DL, Panitch HS, Johnson KP. Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis. Annals of Neurology. 27: 421-7. PMID 2353797 DOI: 10.1002/Ana.410270411 |
0.336 |
|
| 1988 |
Bever CT, McFarland HF, McFarlin DE, Levy HB. The kinetics of interferon induction by poly ICLC in humans. Journal of Interferon Research. 8: 419-25. PMID 2459270 DOI: 10.1089/Jir.1988.8.419 |
0.335 |
|
| Show low-probability matches. |